CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, a biotechnology company developing therapeutics to improve and expand the use of curative hematopoietic stem cell transplantation for more patients, today announced that it has been named by FierceBiotech as one of the Fierce 15 biotechnology companies of 2017. This award designates Magenta Therapeutics as one of the most promising private biotechnology companies in the industry.
“The philosophy of Fierce 15 is a simple one: We want to see the best science combined with the best and brightest management teams," said FierceBiotech editor Ben Adams. “And we want to see that the promise they hold in their hands has—in this industry built on the all or nothing of risk and reward—a genuine chance of being the Next Big Thing.”
“We are honored to be recognized as a Fierce 15 company for our leadership in striving to transform transplant medicine,” said Jason Gardner, D.Phil., chief executive officer, president and co-founder, Magenta Therapeutics. “As we approach the anniversary of Magenta’s launch, this award serves as a testament to our team’s progress and relentless focus on bringing the curative power of hematopoietic stem cell transplant to more patients with autoimmune and rare genetic disorders and hematologic cancers.”
The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's fifteenth annual Fierce 15. Each annual selection highlights privately held companies that are working to develop products, services, or platforms that can advance the biotech industry and transform patient treatment. Companies are selected based on a variety of factors such as the strength of their technology, partnerships, venture backers and a competitive market position.
About Magenta Therapeutics
Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize stem cell transplantation for patients with immune and blood-based diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to stem cell therapies to create patient benefits. Founded by internationally recognized leaders in stem cell transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit www.magentatx.com.
An internationally recognized daily report reaching a network of more than 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every business day, FierceBiotech and its family of publications covers the waterfront in drug development, from pre-clinical science to seed funding and venture capital, through IPOs and licensing, clinical testing, regulatory changes, M&A and beyond.